nach oben

Erschienen in:

01.07.2013 | Original Paper

Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence

Erschienen in: Angiogenesis | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The goal of this study was to develop a molecular imaging agent that can allow for both positron emission tomography (PET) and near-infrared fluorescence (NIRF) imaging of CD105 expression in metastatic breast cancer. TRC105, a chimeric anti-CD105 monoclonal antibody, was labeled with both a NIRF dye (i.e., IRDye 800CW) and ⁶⁴Cu to yield ⁶⁴Cu-NOTA-TRC105-800CW. Flow cytometry analysis revealed no difference in CD105 binding affinity/specificity between TRC105 and NOTA-TRC105-800CW. Serial bioluminescence imaging (BLI) was carried out to non-invasively monitor the lung tumor burden in BALB/c mice, after intravenous injection of firefly luciferase-transfected 4T1 (i.e., fLuc-4T1) murine breast cancer cells to establish the experimental lung metastasis model. Serial PET imaging revealed that fLuc-4T1 lung tumor uptake of ⁶⁴Cu-NOTA-TRC105-800CW was 11.9 ± 1.2, 13.9 ± 3.9, and 13.4 ± 2.1 %ID/g at 4, 24, and 48 h post-injection respectively (n = 3). Biodistribution studies, blocking fLuc-4T1 lung tumor uptake with excess TRC105, control experiments with ⁶⁴Cu-NOTA-cetuximab-800CW (which served as an isotype-matched control), ex vivo BLI/PET/NIRF imaging, autoradiography, and histology all confirmed CD105 specificity of ⁶⁴Cu-NOTA-TRC105-800CW. Successful PET/NIRF imaging of tumor angiogenesis (i.e., CD105 expression) in the breast cancer experimental lung metastasis model warrants further investigation and clinical translation of dual-labeled TRC105-based agents, which can potentially enable early detection of small metastases and image-guided surgery for tumor removal.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRef

Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11:479–497PubMedCrossRef

Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602PubMedCrossRef

Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93SPubMed

Alauddin MM (2012) Positron emission tomography (PET) imaging with ¹⁸F-based radiotracers. Am J Nucl Med Mol Imaging 2:55–76PubMed

Iagaru A (2011) ¹⁸F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging 1:63–64PubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRef

von Elstermann M (2008) Metastasis: which way to the lungs? Nat Rev Cancer 8:410–411CrossRef

Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10:415–424PubMedCrossRef

10.

Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 86:12–19PubMedCrossRef

11.

Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ et al (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14:1931–1937PubMedCrossRef

12.

Eary JF, Hawkins DS, Rodler ET, Conrad EU 3rd (2011) ¹⁸F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 1:47–53PubMed

13.

Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P et al (2012) The clinical use of PET with ¹¹C-acetate. Am J Nucl Med Mol Imaging 2:33–47PubMed

14.

James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897–965PubMedCrossRef

15.

Nolting DD, Nickels ML, Guo N, Pham W (2012) Molecular imaging probe development: a chemistry perspective. Am J Nucl Med Mol Imaging 2:273–306PubMed

16.

Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE et al (2012) Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody. Mol Pharm 9:645–653PubMedCrossRef

17.

Hong H, Zhang Y, Severin GW, Yang Y, Engle JW, Niu G et al (2012) Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with ⁸⁹Zr and IRDye 800CW. Mol Pharm 9:2339–2349CrossRef

18.

Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S et al (2012) ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with ⁸⁹Zr and IRDye 800CW. Am J Transl Res 4:333–346PubMed

19.

Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X et al (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8:135–143PubMedCrossRef

20.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD et al (2012) A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res 18:4820–4829PubMedCrossRef

21.

Cao Q, Cai W, Niu G, He L, Chen X (2008) Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res 14:6137–6145PubMedCrossRef

22.

Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE et al (2012) Positron emission tomography imaging of CD105 expression with ⁸⁹Zr-Df-TRC105. Eur J Nucl Med Mol Imaging 39:138–148PubMedCrossRef

23.

Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2:1–13PubMed

24.

Hong H, Benink HA, Zhang Y, Yang Y, Uyeda HT, Engle JW et al (2011) HaloTag: a novel reporter gene for positron emission tomography. Am J Transl Res 3:392–403PubMed

25.

Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X (2006) In vitro and in vivo characterization of ⁶⁴Cu-labeled Abegrin™, a humanized monoclonal antibody against integrin α_vβ₃. Cancer Res 66:9673–9681PubMedCrossRef

26.

Hong H, Zhang Y, Engle JW, Nayak TR, Theuer CP, Nickles RJ et al (2012) In vivo targeting and positron emission tomography imaging of tumor vasculature with ⁶⁶Ga-labeled nano-graphene. Biomaterials 33:4147–4156PubMedCrossRef

27.

Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ et al (2011) Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38:1335–1343PubMedCrossRef

28.

Wadas TJ, Wong EH, Weisman GR, Anderson CJ (2010) Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 110:2858–2902PubMedCrossRef

29.

Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV et al (2011) Imaging cancer using PET–the effect of the bifunctional chelator on the biodistribution of a ⁶⁴Cu-labeled antibody. Nucl Med Biol 38:29–38PubMedCrossRef

30.

Geus-Oei LF, Oyen WJ (2008) Predictive and prognostic value of FDG-PET. Cancer Imaging 8:70–80PubMedCrossRef

31.

Iagaru A, Masamed R, Keesara S, Conti PS (2007) Breast MRI and ¹⁸F FDG PET/CT in the management of breast cancer. Ann Nucl Med 21:33–38PubMedCrossRef

32.

van Dongen GA, Vosjan MJ (2010) Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 25:375–385PubMedCrossRef

33.

Wu AM (2009) Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med 50:2–5PubMedCrossRef

34.

Zhang Y, Hong H, Orbay H, Valdovinos HF, Nayak TR, Theuer CP, et al. (2013) PET imaging of CD105/endoglin expression with a ^61/64Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging (ePub)

35.

Hong H, Zhang Y, Orbay H, Valdovinos HF, Nayak TR, Bean J, et al. (2013) Positron emission tomography imaging of tumor angiogenesis with a ^61/64Cu-labeled F(ab’)₂ antibody fragment. Mol Pharm (ePub)

Titel: Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence
Publikationsdatum: 01.07.2013
Erschienen in: Angiogenesis / Ausgabe 3/2013
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-013-9344-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis

CD44 regulates vascular endothelial barrier integrity via a PECAM-1 dependent mechanism

p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway

Protein kinase D2 and heat shock protein 90 beta are required for BCL6-associated zinc finger protein mRNA stabilization induced by vascular endothelial growth factor-A

Tumour vasculature targeting agents in hybrid/conjugate drugs